ZA991569B - Derivatives of GLP-1 analogs. - Google Patents

Derivatives of GLP-1 analogs.

Info

Publication number
ZA991569B
ZA991569B ZA9901569A ZA991569A ZA991569B ZA 991569 B ZA991569 B ZA 991569B ZA 9901569 A ZA9901569 A ZA 9901569A ZA 991569 A ZA991569 A ZA 991569A ZA 991569 B ZA991569 B ZA 991569B
Authority
ZA
South Africa
Prior art keywords
glp
analogs
derivatives
present
action
Prior art date
Application number
ZA9901569A
Other languages
English (en)
Inventor
Liselotte Bjerre Knudsen
Per Olaf Huusfeldt
Per Franklin Nielsen
Freddy Zimmerdahl Pedersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA991569B publication Critical patent/ZA991569B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
ZA9901569A 1998-02-27 1999-02-26 Derivatives of GLP-1 analogs. ZA991569B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK26898 1998-02-27

Publications (1)

Publication Number Publication Date
ZA991569B true ZA991569B (en) 1999-08-27

Family

ID=8091634

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA9901570A ZA991570B (en) 1998-02-27 1999-02-26 Partially structured micellar-like GLP-1 aggregates.
ZA9901569A ZA991569B (en) 1998-02-27 1999-02-26 Derivatives of GLP-1 analogs.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA9901570A ZA991570B (en) 1998-02-27 1999-02-26 Partially structured micellar-like GLP-1 aggregates.

Country Status (7)

Country Link
EP (1) EP1060191B1 (de)
JP (1) JP2002512175A (de)
AT (1) ATE466027T1 (de)
AU (1) AU2610699A (de)
DE (1) DE69942306D1 (de)
WO (1) WO1999043706A1 (de)
ZA (2) ZA991570B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932535A3 (de) 1998-07-31 2008-10-29 Novo Nordisk A/S Anregung der Beta-Zellbildung
EP1634605A3 (de) 2000-03-08 2006-10-11 Novo Nordisk A/S Behandlung von Dyslipämie bei einem Patienten mit Typ 2 Diabetes
ATE346093T1 (de) 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
EP1346722B1 (de) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
CA2434237C (en) 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
WO2002069994A2 (en) 2001-03-07 2002-09-12 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
MXPA04001525A (es) 2001-08-23 2004-05-31 Lilly Co Eli Analogos de peptido -1 similar al glucagon.
EP1432430A4 (de) * 2001-08-28 2006-05-10 Lilly Co Eli Vormischungen von glp-1 und basalinsulin
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
JP2005508360A (ja) * 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１およびインスリンの二相混合物
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
CA2468700A1 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
RU2332229C2 (ru) 2002-02-20 2008-08-27 Эмисфире Текнолоджис Инк. Способ введения молекул glp-1
AU2003272970B2 (en) 2002-10-11 2009-05-28 Sanwa Kagaku Kenkyusho Co. Ltd. GLP-1 derivatives and transmicosal absorption preparations thereof
WO2004069314A1 (en) 2003-02-04 2004-08-19 Novo Nordisk A/S Injection device with rotatable dose setting
DE602004025205D1 (de) * 2003-02-19 2010-03-11 Ipsen Pharma Glp-1-analoga
AU2004231461B2 (en) * 2003-03-19 2009-11-12 Eli Lilly And Company Polyethelene glycol linked GLP-1 compounds
CN102174102A (zh) 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
ES2380437T3 (es) 2003-06-03 2012-05-11 Novo Nordisk A/S Composiciones farmacéuticas de péptido GLP-1 estabilizadas
ATE529126T1 (de) 2003-06-03 2011-11-15 Novo Nordisk As Stabilisierte pharmazeutische peptid zusammensetzungen
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
MXPA06005581A (es) 2003-11-20 2006-08-11 Novo Nordisk As Formulaciones de peptidos que contienen propilenglicol que son optimas para la produccion y uso en dispositivos de inyeccion.
JP4865565B2 (ja) * 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
EP2210900A3 (de) * 2003-12-16 2010-08-11 Ipsen Pharma GlLP-1-Analoga
RU2006120079A (ru) 2003-12-18 2008-01-27 Ново Нордиск А/С (DK) Производные глюкагоноподобного пептида-1 (glp-1)
MXPA06007667A (es) 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
AU2005203925A1 (en) 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-Like Peptide-1 analogs with long duration of action
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
EP1758575A1 (de) 2004-06-11 2007-03-07 Novo Nordisk A/S Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
ES2442223T3 (es) 2004-08-31 2014-02-10 Novo Nordisk A/S Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
JP2008515856A (ja) * 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
WO2006051110A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
MX2008000255A (es) 2005-07-14 2008-04-02 Novo Nordisk As Activadores de urea glucocinasa.
EP1996224B1 (de) 2006-03-15 2012-11-07 Novo Nordisk A/S Mischungen aus amylin und insulin
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
EP2170945A1 (de) 2007-07-16 2010-04-07 Novo Nordisk A/S Proteasestabilisierte pegylierte insulinanaloga
DK2597103T3 (en) 2007-11-16 2017-02-13 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
EP2344519B1 (de) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminale fragmente von glucagon-ähnlichem peptid-1 (glp-1)
WO2011052523A1 (ja) 2009-10-30 2011-05-05 大塚化学株式会社 抗原性ｇｌｐ－１アナログの糖鎖付加体
DK2513140T3 (en) * 2009-12-16 2016-01-18 Novo Nordisk As Double-acylated GLP-1 derivatives
EP2555791B1 (de) 2010-04-09 2017-11-01 Sinai Health System Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
KR20130093470A (ko) 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
EP2637699B1 (de) * 2010-11-09 2018-05-16 Novo Nordisk A/S Zweifach acylierte glp-1-derivate mit einem linker
DK3326620T3 (da) 2010-12-16 2020-05-25 Novo Nordisk As Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
KR102093463B1 (ko) * 2011-04-12 2020-03-26 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
MX355361B (es) * 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
EP2729157B1 (de) 2011-07-06 2019-01-16 The General Hospital Corporation Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
CN107266558A (zh) * 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
US20150038417A1 (en) 2011-12-09 2015-02-05 Novo Nordisk A/S GLP-1 Agonists
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP4331667A2 (de) 2012-03-22 2024-03-06 Novo Nordisk A/S Zusammensetzungen mit einem abgabemittel und herstellung davon
CN104411322B (zh) 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
CN104519902B (zh) * 2012-05-08 2017-10-27 诺和诺德股份有限公司 双酰化glp‑1衍生物
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US20150273069A1 (en) 2012-10-17 2015-10-01 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
KR20160021183A (ko) 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
MX2015016875A (es) * 2013-07-04 2016-04-07 Novo Nordisk As Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos.
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
EP3006045B3 (de) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmazeutische Formulierungen zur oralen Verabreichung von Peptid- oder Proteinarzneimitteln
CN106999602B (zh) 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
EP3233898A1 (de) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1-derivate und verwendungen davon
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
US20200188479A1 (en) * 2017-03-08 2020-06-18 Intarcia Therapeutics, Inc. Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
TWI783890B (zh) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
KR20200141469A (ko) 2018-04-05 2020-12-18 썬 파마슈티칼 인더스트리스 리미티드 신규한 glp-1 유사체
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
EP3938037A1 (de) 2019-03-15 2022-01-19 Diet4Life ApS Kombination von diätetischen peptiden
KR20220143037A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 Glp-1 조성물 및 이의 용도
JP2023524695A (ja) 2020-04-29 2023-06-13 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
CN116419750A (zh) 2020-09-07 2023-07-11 西普鲁梅有限公司 改进的glp-1受体激动剂的药物制剂
KR20230083294A (ko) 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
IL303969A (en) 2021-01-24 2023-08-01 David Forrest Michael ugh
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
CA1341320C (en) 1986-05-05 2001-11-20 Joel Habener Insulinotropic hormone
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
ATE193541T1 (de) 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate

Also Published As

Publication number Publication date
JP2002512175A (ja) 2002-04-23
DE69942306D1 (de) 2010-06-10
ATE466027T1 (de) 2010-05-15
ZA991570B (en) 1999-09-02
WO1999043706A1 (en) 1999-09-02
EP1060191B1 (de) 2010-04-28
EP1060191A1 (de) 2000-12-20
AU2610699A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
ZA991569B (en) Derivatives of GLP-1 analogs.
WO1999002514A3 (en) Epothilone derivatives
BG105967A (en) C(7) ester substituted taxanes and their use as antitumor agents
EG24968A (en) Prodrugs of 4-phenyl-pyridine derivatives.
HN1998000036A (es) Compuesto de pirazina
DE69224712D1 (de) Verschleissfeste, flammhemmende Zusammensetzungen
IL135590A (en) Process for the reduction of oxiranyl epothilones to olefinic epothilones
MY132129A (en) Polyarylcarboxamides useful as lipid lowering agents
MY117805A (en) Resorcinol derivatives
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
MX9605206A (es) 1alfa,26-dihidroxi-d-homo-vitamina d3.
IL141328A0 (en) Pantoprazole magnesium dihydrat
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
DK0915819T3 (da) Illudinanaloger anvendt som antitumormiddel
BG105197A (en) Polymorph form of a medicament
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
ZA200110487B (en) Vitamin D3 Analogs.
IL106748A0 (en) 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
ZA997705B (en) Production methof of isoxazolidinedione compound.
UA66866C2 (uk) Синтез морфолінових похідних
BG106016A (en) Resorcinol derivatives
AU2001296775A1 (en) Triptycene analogs
EA200100564A1 (ru) Препарат, снижающий выделение пролактина
BG105964A (en) C(10) carbonate substituted taxanes and their use as antitumor agents
PL352063A1 (en) Derivatives (of benzodioxane, benzophurane or benzopyrane) substituted by pyrolydinylene, piperydinylene or homopiperydinylene